8-KLeadership ChangesExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Executive Changes (Jul 5, 2016)

Filed July 5, 2016For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) filed an 8-K on July 5, 2016, to announce a key addition to its Board of Directors. Leslie S. Heisz was appointed to the Board, effective immediately, and will also serve as a member of the Audit Committee. This appointment is significant as it brings new expertise to the company's governance and oversight functions, particularly within the critical Audit Committee, which is responsible for financial reporting integrity and internal controls. Ms. Heisz's appointment is straightforward, with no disclosed arrangements or understandings regarding her selection, nor any material direct or indirect interests in transactions requiring disclosure. She will be compensated in line with the company's existing non-employee director compensation structure, as detailed in the 2016 Proxy Statement. Investors should view this as a positive development, indicating the Board's commitment to maintaining strong leadership and governance as the company continues its operations.

Key Highlights

  • 1Appointment of Leslie S. Heisz to the Board of Directors, effective July 5, 2016.
  • 2Ms. Heisz appointed as a member of the Audit Committee.
  • 3No disclosed arrangements or understandings related to Ms. Heisz's selection.
  • 4No material direct or indirect interest in any transactions requiring disclosure by Ms. Heisz.
  • 5Ms. Heisz to receive standard compensation for non-employee directors.
  • 6The press release announcing her appointment is filed as an exhibit (Exhibit 99.1).

Frequently Asked Questions

Leslie S. Heisz has been appointed to the Board of Directors of Edwards Lifesciences Corporation, effective July 5, 2016. She has also been appointed as a member of the Board's Audit Committee.

There are no disclosed arrangements or understandings between Ms. Heisz and any other persons regarding her selection. She also has no direct or indirect material interest in any transactions requiring disclosure. Ms. Heisz will receive the same compensation as other non-employee directors, as outlined in the company's 2016 Proxy Statement.

Her appointment to the Audit Committee is significant as this committee plays a crucial role in overseeing financial reporting, internal controls, and the audit process. This suggests a focus on maintaining strong financial governance and oversight at Edwards Lifesciences.